Moleculin Biotech (NASDAQ:MBRX) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRXGet Rating) in a research report issued on Monday. The firm set a “sell” rating on the stock.

MBRX opened at $1.59 on Monday. The stock’s 50 day simple moving average is $1.62 and its 200 day simple moving average is $1.87. Moleculin Biotech has a 1 year low of $1.22 and a 1 year high of $3.99. The firm has a market cap of $45.44 million, a price-to-earnings ratio of -2.69 and a beta of 1.90.

Moleculin Biotech (NASDAQ:MBRXGet Rating) last issued its quarterly earnings data on Friday, March 25th. The company reported ($0.17) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.04. On average, equities research analysts anticipate that Moleculin Biotech will post -0.94 EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of MBRX. Morgan Stanley bought a new stake in shares of Moleculin Biotech in the first quarter worth $39,000. Goldman Sachs Group Inc. bought a new stake in Moleculin Biotech during the second quarter valued at about $94,000. Citadel Advisors LLC grew its holdings in Moleculin Biotech by 174.9% during the second quarter. Citadel Advisors LLC now owns 38,053 shares of the company’s stock valued at $140,000 after purchasing an additional 24,210 shares during the period. Geode Capital Management LLC grew its holdings in Moleculin Biotech by 3.4% during the third quarter. Geode Capital Management LLC now owns 245,612 shares of the company’s stock valued at $736,000 after purchasing an additional 8,026 shares during the period. Finally, Sigma Planning Corp purchased a new position in shares of Moleculin Biotech in the fourth quarter valued at about $80,000. 10.09% of the stock is owned by institutional investors and hedge funds.

Moleculin Biotech Company Profile (Get Rating)

Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.

Further Reading

Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.